SummaryJust-released valvular heart disease guidelines favor transcatheter interventions for the right patient and more shared decision-making among heart teams, physicians and severe aortic stenosis patients with an eye toward types of valves and approaches, and lifetime benefits and risks. The 2020 ACC/AHA Heart Valve Disease Guidelines mark a change from the 2014 version and 2017 focused update and open a path to more frequent revisions going forward. The guidelines also offer more evidence and insight for physicians on patients 65-80 and people over 80 for whom transfemoral TAVR is now an option. This panel of five leading experts who treat VHD unpacks the changes around evaluating and testing patients with severe AS, treating patients at comprehensive valve centers, utilizing anticoagulants and why less invasive procedures have replaced surgery for many patients.
| What You'll Learn
Target Audience
|
Expert Panel
ModeratorMichael J. Reardon, MDChair of Cardiovascular Research | John P. Erwin, III, MDDepartment of Internal Medicine | Purvi Parwani, MDDirector, Women’s Cardiovascular Health Clinic | Mark J. Ricciardi, MDDirector of Interventional Cardiology & Structural Heart Disease | Paul Sorajja, MDDirector of the Center for Valve and Structural Heart Disease |